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Abstract 
Background: Healthcare associated infections (HAI) with multidrug‑resistant (MDR) bacteria continue to be a global 
threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and 
cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria.
Methods: Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and 
four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, 
formulations were tested against Gram‑positive and Gram‑negative bacteria implicated in HAI. Formulations with MIC 
values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis 
assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for syner‑
gistic activity with a standard antibiotic was also probed.
Results: Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active 
lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin 
resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 
(CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/
mL) and lowered the vancomycin MIC for VRE from 32–64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and 
CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against 
HepG2 cells when applied at 100 μg/mL over 48 h.
Conclusions: Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids 
exhibit antibacterial activity against Gram‑positive and Gram‑negative bacteria and may augment the activity of anti‑
biotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid car‑
rier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential 
as novel lipophilic antimicrobial agents.
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Background
Healthcare associated infections (HAI) are one of the 
leading causes of preventable deaths in the US, and pre-
sent a significant economic burden in healthcare costs. 
Warnings regarding infectious agents developing into 
multidrug-resistant forms and the possibility of future 
pandemic outbreaks have been repeatedly issued by the 
Centers for Disease Control and Prevention and the 
World Health Organization. The global dissemination 
of drug resistant carbapenemase-producing Enterobac-
teriaceae in the healthcare setting [1] is just one of the 
more recent examples. Other causes of HAI with mul-
tidrug-resistant bacteria include methicillin-resistant 
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Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus faecalis (VRE), Pseudomonas aeruginosa, 
and Acinetobacter baumannii [2]. Multidrug-resist-
ant Staphylococcus epidermidis has become notori-
ous for catheter associated infections. Nationwide, at 
least one case of HAI occurs for every 25 patients [3]. 
Despite some progress in containing the occurrence of 
HAI through infection control measures [4], an urgent 
need for the development of novel antibacterial agents 
remains. No new class of antibiotic has been discov-
ered since 1987 and the last six approved new drugs are 
all modifications of existing drugs [5, 6]. Drug discovery 
through target-focused screening of large libraries of syn-
thetic compounds has failed with a major reason being 
insufficient compound penetration into the microbial 
cell [7], and transition of natural antimicrobial peptides 
to the clinical market has proven to be difficult [8, 9]. 
Ongoing efforts include antisense RNA targeting essen-
tial microbial genes [10] and exploitations of uncultured 
bacteria [11]. However, host derived lipids, increasingly 
recognized as important antimicrobial effectors of the 
innate host defense [12, 13], might also be exploited for 
novel drug design.
Lipids are a widely heterogeneous group of molecules 
that share hydrophobic or mixed hydrophobic/hydro-
philic properties [14]. The major lipid classes include: 
fatty acids- the basic building blocks for more complex 
lipids, cholesteryl esters, and phospholipids. Cholesteryl 
esters are formed through esterification of a fatty acid to 
cholesterol. Phospholipids typically consist of a glycerol 
with two fatty acid residues attached, a phosphate group 
and additions such as choline, an alcohol, or amines. The 
antimicrobial activity of fatty acids has been known for 
some time (reviewed in [15]) while antimicrobial proper-
ties of cholesteryl esters have been more recently discov-
ered [16].
Motivated by the urgent need for novel antibacte-
rial strategies, the main objective for this study was to 
examine whether lipids identified as antibacterial effec-
tors in body fluids may have a potential to be used in 
innovative drug design. Due to their inherent hydropho-
bicity, lipids require carriers in aqueous environments. 
Liposomes have been used in the past for delivery of 
compounds with hydrophobic properties [17] offering 
in some cases the benefit of reducing cytotoxicity [18]. 
Liposomes are phospholipid vesicles where the polar 
head groups of phospholipids interact with the aque-
ous outer environment and the fatty acid tails provide 
a hydrophobic environment for lipophilic compounds. 
When used as carrier, liposomes also provide the advan-




The following strains were purchased from Ameri-
can Type Culture Collection (ATCC, Manassas, VA, 
multidrug-resistant S. epidermidis ATCC 700566, 
methicillin resistant S. aureus ATCC 33591 (MRSA), 
vancomycin resistant E. faecalis ATCC 700802 (VRE), 
E. cloacae ATCC 49141, P. aeruginosa ATCC 9027, and 
A. baumanii ATCC 19606. In addition, a clinical cystic 
fibrosis isolate of P. aeruginosa (PACF, Welsh laboratory, 
University of Iowa; also described in [16]) was used. Stock 
cultures were stored at −80  °C using the CryoSaver sys-
tem (Hardy Diagnostics, Santa Maria, CA). For each assay, 
isolated colonies subcultured from freshly thawed bacte-
ria were used to inoculate the ATCC recommended broth 
media purchased from Becton, Dickinson, and Company 
(BD, Franklin Lakes, NJ; nutrient broth for MRSA and 
A. baumannii, brain heart infusion for VRE, tryptic soy 
broth for the remainder). After overnight culture at 37 °C 
(20–24 h for A. baumannii, 16–18 h for others) bacteria 
were adjusted to McFarland 0.5 in 140 mM NaCl, diluted 
100-fold, and inoculated into 1.1-fold concentrated cat-
ion-adjusted Mueller–Hinton broth (MHB+  , Teknova, 
Hollister, CA) to yield 5 × 105 CFU/mL.
Antibiotics
Oxacillin, cefotaxime, vancomycin, tetracycline, and 
ciprofloxacin were purchased from Sigma-Aldrich in 
salt form, dissolved in dH2O, and kept as stock solution 
(10 mg/mL) at −20 °C.
Lipids
Lipids investigated (test lipids, Table  1) included free 
fatty acids (palmitic, stearic, oleic, linoleic, arachi-
donic, and docosahexaenoic acid) and cholesteryl esters 
(cholesteryl palmitate, -oleate, -linoleate, and -arachi-
donate) and were purchased from Sigma-Aldrich, St. 
Louis, MO. Carrier lipids included phospholipids and 
cholesterol. The phospholipids 1,2-dimyristoyl-sn-glyc-
ero-3-phosphatidylcholine (DMPC), 1,2-dipalmitoyl-sn- 
glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glyc-
ero-3-phosphatidyl-(10-rac-glycerol) (DSPG), and Hydro-
genated Soy Phosphatidylcholine (HSPC; SPC-3) were 
purchased from Lipoid GmbH, Ludwigshafen, Germany. 
The phospholipid 1,2-dimyristoyl-sn-glycero-3-phosphati-
dyl-(10-rac-glycerol) (DMPG) was purchased from Nip-
pon Fine Chemical, Osaka, Japan, and cholesterol from 
NOF Corporation, Tokyo, Japan.
Liposome preparation
Six different carrier liposome formulations (carrier-1–6) 
were generated using the phospholipids and cholesterol 
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listed above (carrier 1: HSPC; carrier 2: DPPC; carrier 
3: DMPC; carrier 4: HSPC:DSPG [0.75:0.5]; carrier 5: 
DPPC:cholesterol [0.8:0.05]; carrier 6: HSPC:cholesterol 
[0.70:0.10], all in molar ratios). Principles of the liposome 
preparation have been described more in detail earlier 
[21]. Liposomes were prepared by dissolving the car-
rier and test lipids (0.8:0.2, respectively) in chloroform/
methanol (1:1 v/v). The organic solvents were evaporated 
under a stream of nitrogen gas at 65 °C, and residual sol-
vent removed in vacuo for >24 h. Unilamellar liposomes 
were formed by hydrating the lipid films with 9 % sucrose 
and probe sonicating until translucent. The liposomes 
were then sterilized by passage through a 0.22 µm filter. 
Each liposome preparation was characterized by dynamic 
light scattering (UPA 150, Microtrac, Montgomeryville, 
PA; see Additional file  1: Table S1). Liposomes were 
stored in 9  % sucrose at 1  mg/mL test lipid (5–10  mg 
total lipid/mL) for up to 6 month at 4 °C. As a control 9 % 
sucrose was used. When necessary, liposomal formula-
tions containing test lipids were diluted with 9 % sucrose 
to ten-fold concentrated working stocks. Stock solutions 
for the respective carrier liposomes without test lipids 
were diluted so that the phospholipid concentration was 
the same as the phospholipid concentration in the formu-
lations with test lipid.
Determination of minimal inhibitory concentration (MIC)
Following Clinical and Laboratory Standards Institute 
M07-A9 for broth microdilution assay [22], 10  μL ali-
quots of serially diluted 10-fold concentrated antibi-
otic were added to general assay 96 well- round bottom 
polystyrene microtiter plates followed by the addition of 
90  μL of diluted bacteria as prepared in above. For ste-
rility control, 1.1-fold cation-adjusted Mueller–Hinton 
broth (MHB+) without bacteria was included in the test-
ing. The plates were then incubated at 37 °C for 16–24 h, 
as recommended, in air and turbidity was read at 650 nm. 
MIC was the lowest concentration of antibiotic that pre-
vented growth reflected in measurable turbidity.
Modified minimal inhibitory concentration assay
Due to the inherent turbidity of the liposomal formula-
tions interfering with absorbance readings, the MIC pro-
tocol was modified; after completion of the MIC assay 
the DNA content was quantified with the fluoroprobe 
Syto9 (Invitrogen, Carlsbad, CA). Syto9 freely crosses 
cell membranes and binds to DNA upon which green 
fluorescence is emitted. The degree of fluorescence cor-
relates with the amount of DNA, thus with the bacterial 
concentration in a sample, regardless of sample turbidity 
contributed by the liposomal formulations [16]. Using 
black untreated 96 well microtiter plates with clear flat 
bottom wells (Costar, Corning Life Sciences, Union City, 
CA) bacteria were otherwise prepared, mixed with anti-
biotics or liposomes, and incubated according to the 
standard MIC procedure. Each assay included a growth 
control (incubation of bacteria in MHB+) and a killing 
control (incubation of bacteria with effective antibiotic). 
In addition, liposomes and antibiotics were incubated in 
the absence of bacteria to control for sterility of the rea-
gents and to obtain background fluorescence readings. 
At the end of the incubation period, 100 μL of 1.25 μM 
Syto9 (diluted in dH2O) was added to each well. After 
15  min incubation at RT in the dark, relative fluores-
cence units (RFU) were measured (485 nmex/530 nmem; 
Tecan GENios, Tecan Systems, Inc., San Jose, CA). RFUs 
obtained from liposomal formulations or antibiotic incu-
bated in medium without bacteria (background fluores-
cence) were subtracted from the RFUs obtained from 
corresponding wells with bacteria present. All liposomal 
formulations were first screened at 64  μg/mL test lipid. 
Those formulations that, compared to untreated bacteria, 
Table 1 Lipids investigated in this study
a As provided by the manufacturer
b Number of unsaturated double bonds in the free or esterified fatty acid
Lipid class Test lipid Code Molecular formula Molecular weighta Double bondsb
Free fatty acids Palmitic acid PA C16H32O2 256.42 0
Stearic acid SA C18H36O2 284.48 0
Oleic acid OA C18H34O2 282.46 1
Linoleic acid LA C18H32O2 280.45 2
Arachidonic acid AA C20H32O2 304.47 4
Docosahexaenoic acid DA C22H32O2 328.49 6
Cholesteryl esters Cholesteryl palmitate CP C43H76O2 625.06 0
Cholesteryl oleate CO C45H78O2 651.10 1
Cholesteryl linoleate CL C45H76O2 649.08 2
Cholesteryl arachidonate CA C47H76O2 673.11 4
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effected at least 95  % reduction of RFUs of at least two 
different bacterial strains were further investigated. They 
were subjected to serial dilution and determination of 
modified MIC. Modified MIC was defined as the lowest 
concentration of liposomal formulation that produced 
RFUs at background level.
Determination of minimal bactericidal concentration 
(MBC)
After completion of the MIC assay, 6 µL of each well was 
serially diluted and spot plated. Based on Clinical and 
Laboratory Standards Institute guidelines M26-A [23], 
concentrations of liposomal formulations that reduced 
growth to less than 15 colony forming units (CFU)/6 μL 
or 2500 CFU/mL were considered bactericidal.
Vancomycin synergism
The protocol for the modified MIC assay was employed 
with the following changes: instead of 10  μL of tenfold 
concentrated antibiotic or test lipid, 5 µL of 20-fold con-
centrated antibiotic and 5  µL of 20-fold concentrated 
test lipid was used. First, the MIC of vancomycin applied 
alone was established for VRE and then, serially diluted 
vancomycin was tested in the presence and absence of 
5 μg/mL cholesteryl linoleate in carrier 3.
Hemolytic activity testing
Sheep red blood cells (RBCs) at 50  % v/v whole blood 
in Alsever’s solution (Sigma-Aldrich) were washed by 
repeated centrifugation at 500×g and resuspension in 
saline (0.9  % w/v) until the absorbance of supernatant 
at 405 nm equaled the absorbance of saline. On the final 
wash, RBCs were adjusted to 15 % packed cell volume in 
normal saline (15 parts sedimented RBC plus 85 parts 
saline). In microplates, 10  μL of this was then added to 
90 μL liposomal formulations or carrier which had been 
diluted in saline to the desired test concentration. As 
negative control, RBCs were mixed with saline. To obtain 
maximal (100 %) hemolysis, Triton X-100 (Fisher Scien-
tific) was added to 1 % final concentration. Samples were 
then incubated at 37 °C, 7.5 % CO2 for up to 24 h. At the 
end of each incubation period (30 min, 3 h, and 24 h), the 
percent hemolysis was estimated by the quantification of 
liberated hemoglobin by absorbance reading. To prevent 
errors due to liposomal components affecting the oxida-
tion state of the hemoglobin (and thus the absorbance 
reading) and to dissociate all major hemoglobins from 
other sample components (also affecting the absorb-
ance reading), all hemoglobin species were converted to 
hematin based on the Alkaline Hematin Detergent—575 
method [24]. Briefly, intact cells were pelleted by centrif-
ugation at 4500×g and the resulting supernatants were 
diluted to 50  % v/v in 1  % Triton-X-100/0.5  M NaOH. 
Absorbance at 405  nm (Soret band) was measured in a 
Multiskan Ascent plate reader. After blanking with 50 % 
saline v/v in 1 % Triton X-100/0.5 M NaOH, the percent 
hemolysis was calculated, as follows: % H  =  (absorb-
ance of treatment sample/absorbance of 100 % hemolysis 
sample) × 100.
Cytotoxicity testing
Cytotoxic activity of liposomal formulations was assessed 
with a hepatic cell line that is commonly used for this 
purpose [25]. HepG2 cells (ATCC, Manassas, VA) were 
maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10  % fetal bovine serum, 
1000  IU/mL penicillin, 100  μg/mL streptomycin and 
2  mM  l-glutamine (Invitrogen, Carlsbad, CA) in tis-
sue culture flasks at 37  °C with 5  % CO2. Assays were 
performed in 96-well flat bottom tissue culture treated 
plates (Corning, Cambridge, MA). For passing, cells 
grown to 80  % confluency were detached with 0.25  % 
trypsin/0.53 mM EDTA (Cellgro, Mediatech, Inc, Manas-
sas, VA) for 3  min, centrifuged at 1000×g for 8  min at 
23 °C, and after resuspension in culture medium split at a 
ratio of 1: 4. For experiment seeding, cells were detached 
and spun as above, adjusted to 5 ×  105 viable cells/mL, 
and aliquoted at 100  μL per well. After incubation for 
18–24 h, until 80 % confluency had been reached, super-
natants were removed and replaced with 100 μL of lipo-
some treatment (liposomal formulations in 9  % sucrose 
at 1000  μg/mL test lipid further diluted 1:10 in culture 
medium to yield a final concentration of 100 μg/mL test 
lipid). Stocks for carrier liposomes were diluted so that 
their phospholipid concentration was the same as the 
phospholipid concentration of the test lipid in its respec-
tive formulation. As negative control, 9 % sucrose diluted 
1:10 in culture medium was used. After 48  h incuba-
tion at 37 °C with 5 % CO2 cell viability was determined 
with the XTT assay (Roche Diagnostics Pleasanton, CA) 
according to the manufacturer’s instructions. Previously 
untreated cells that were incubated for 15 min with 0.1 % 
Triton X 100 immediately prior to the XTT assay were 
used as positive control for cytotoxicity. Cytotoxic activ-
ity of lipids was quantified based on the inhibition of cell 
proliferation after lipid treatment relative to untreated 
cells.
Data analysis
MIC and MBC assays were conducted in duplicates and 
repeated at least once. Hemolysis assays were performed 
in triplicate and cytotoxicity assays were conducted in 
replicates of four and repeated for a total of three inde-
pendent experiments. Microsoft Excel 2013 was used for 
raw data analysis and graphing. IBM SPSS Statistics ver-
sion 20 was used for statistical analysis.
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Results
Validation of modified MIC assay with fluorescence 
readout
Due to their hydrophobicity- in particular cholesteryl 
esters cannot be dissolved in aqueous media- test lipids 
were incorporated into carrier liposomes. Six differ-
ent formulations designated as carrier 1–6 were tested. 
The particulate nature of liposomes interferes with tur-
bidity readings which are routinely used in standard 
MIC assays to evaluate bacterial growth in the presence 
and absence of antibiotics. Therefore, in this study, we 
employed a modified antimicrobial susceptibility testing 
assay that utilizes the green fluorescent DNA probe Syto9 
to quantify bacterial proliferation [16]. As summarized 
in Table 2, the modified assay with fluorescence readout 
produces MICs that were mostly comparable to those 
determined with standard MIC testing, with both sets 
of MIC values within acceptable ranges as defined by the 
Clinical and Laboratory Standards Institute.
Spectrum of activity of liposomal formulations
First, all formulations were screened at 64  μg/mL test 
lipid (free fatty acids or cholesteryl esters) against bac-
terial strains that cause HAI and are resistant to multi-
ple antibiotics (Table 3). For comparison, a P. aeruginosa 
strain previously reported to be susceptible to cholesteryl 
esters (PACF, [16]) was also used. When test lipids were 
serially diluted, the corresponding carrier lipids were 
similarly diluted maintaining the ratio of test lipid to 
carrier lipid. For each test lipid the corresponding carrier 
formulation itself was also assayed at the equivalent con-
centration. Of note, the liposome size was influenced by 
the lipid species (see Additional file 1: Table S1).
Based on an at least 80 % inhibition threshold, overall, 
test liposomes were more effective against the Gram-posi-
tive strains tested than the Gram-negative strains. Among 
the Gram-positive bacteria tested, S. epidermidis and VRE 
were inhibited by several formulations representing both 
fatty acids, in particular PA4 and SA4, and cholesteryl 
esters (CL3 and CA4 for S. epidermidis and VRE, respec-
tively). Among the Gram-negative bacteria tested, one of 
the two P. aeruginosa strains and the A. baumannii strain 
were completely resistant to all lipids tested. Furthermore, 
the E. cloacae strain was inhibited only by two fatty acid 
formulations (LA4, AA4) and one cholesteryl ester for-
mulation (CL3). However, the cystic fibrosis isolate of P. 
aeruginosa exhibited broad susceptibility to several fatty 
acid and cholesteryl ester formulations suggesting that 
there is a strain dependent susceptibility. In general, test 
lipids prepared with carrier 3 and carrier 4 demonstrated 
the greatest activity. There was also some inhibitory activ-
ity of the carrier lipids independent from the presence of 
fatty acids or cholesteryl esters (see Table 3).
Those test lipid formulations that effected at least 95 % 
growth inhibition against at least two different bacte-
rial strains in the screening assay were further subjected 
to determination of minimal inhibitory concentration 
(Table  4). The lowest MIC values were determined for 
Table 2 Validation of  the modified antimicrobial susceptibility testing assay employing the DNA binding fluoroprobe 
Syto9
a Designated ATCC quality control strains for antimicrobial susceptibility testing
b Shown are the values derived from two independent experiments each conducted in triplicate
c According to Clinical and Laboratory Standards Institute M100-S22 for broth microdilution assay
Strainsa Antibiotic MIC (μg/mL)b
Expectedc Measured
Standard assay Modified assay
S. aureus ATCC 29213 Oxacillin 0.12–0.5 0.0625 0.5
Cefotaxime 1–4 1–2 2
Tetracycline 0.12–1 0.125–0.25 0.5
Ciprofloxacin 0.12–0.5 0.25–0.5 0.5
E. faecalis ATCC 29212 Oxacillin 8–32 0.5–2 8–16
Tetracycline 8–32 16 16
Ciprofloxacin 0.25–1 0.5–1 2
E. coli ATCC 25922 Cefotaxime 0.03–0.12 0.125 0.125
Tetracycline 0.5–2 1 2–4
Ciprofloxacin 0.004–0.015 0.0156 0.0156
P. aeruginosa ATCC 27853 Cefotaxime 8–32 8 16
Tetracycline 8–32 16 16–32
Ciprofloxacin 0.25–1 0.25 0.5–1
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formulations PA4, SA4, and CL3 for S. epidermidis and 
VRE. The MIC for PA4 was 0.5 μg/mL against S. epider-
midis and 2  μg/mL against VRE. The MIC for SA4 was 
0.25 μg/mL against S. epidermidis and 0.5 μg/mL against 
VRE. For CL3 the MIC was 1  μg/mL against S. epider-
midis and 8  μg/mL against PACF. The activity of LA3 
Table 3 Screening of liposomal formulations for antibacterial activity
Test lipids (see Table 1 for abbreviations) prepared in carrier liposomes formulations #1–6 with unique phospholipid composition (TL) and carrier liposomes without 
test lipid (CR) were screened against bacterial strains relevant to healthcare associated infections (SE multidrug-resistant Staphylococcus epidermidis ATCC 700566, 
MRSA methicillin resistant Staphylococcus aureus ATCC 33591, VRE vancomycin resistant Enterococcus faecalis ATCC 700802, ENC Enterococcus cloacae ATCC 49141, PA 
Pseudomonas aeruginosa ATCC 9027, PACF Pseudomonas aeruginosa, cystic fibrosis isolate [16], AB Acinetobacter baumanii ATCC 19606). All test lipids where employed 
at 64 μg/mL. The corresponding carrier lipid concentrations were about 10–12 times higher for fatty acid formulations and 4–5 times higher for cholesteryl ester 
formulations. Bacterial growth was quantified based on relative fluorescence units (RFU) of the DNA probe Syto 9. Italics 80–95 % growth inhibition; Bolded and in 
italics >95 % growth inhibition. Data represent means of the % inhibition compared to untreated bacteria from two independent experiments conducted each in 
triplicate. ID Liposome identification, for example PA1 stands for palmitic acid prepared in carrier liposomes # 1
NT not tested
ID SE MRSA VRE ENC PACF PA AB
TL CR TL CR TL CR TL CR TL CR TL CR TL CR
PA1 64 −11 62 75 53 −89 −14 −80 4 32 20 13 23 −93
PA3 67 3 69 82 99 −63 14 −56 84 92 28 5 0 −91
PA4 100 8 32 62 99 −90 −10 6 3 15 41 45 35 −59
PA6 66 −11 42 59 65 −85 7 −48 12 34 −17 −22 46 −58
SA1 15 −14 63 63 −76 −91 22 −72 0 10 −7 18 28 −76
SA3 −28 −8 64 72 83 −78 22 −93 70 93 27 7 26 −60
SA4 100 7 38 64 100 −99 −18 −11 12 19 44 47 31 −63
SA6 5 −61 46 50 −25 −86 −30 −143 −16 27 −22 −25 29 −81
OA1 32 −21 62 79 40 −142 56 −60 22 38 −1 8 17 −77
OA3 50 −49 80 83 50 −41 −66 −117 87 93 −9 4 14 −92
OA4 31 −26 59 79 55 −58 −7 −25 12 17 52 45 31 −84
OA6 −10 0 66 59 −12 −18 44 30 11 25 −25 −21 1 −72
LA1 5 −27 49 70 25 −156 −31 −121 8 46 −6 12 18 −70
LA3 100 −57 55 83 18 −62 −37 −399 97 93 12 1 29 −61
LA4 86 −32 60 79 94 −101 89 −103 10 20 5 45 0 −75
LA6 9 −37 45 57 45 −156 −140 −135 2 25 −34 −26 22 −81
AA1 −37 51 48 73 66 −14 79 34 −1 44 −5 6 31 −85
AA3 72 94 50 82 −8 −40 −6 8 91 94 −17 −8 34 −57
AA4 65 36 85 84 89 43 95 54 15 18 51 47 33 −55
AA6 45 −69 45 58 33 −91 −1 −131 −8 14 −29 −20 34 −55
DA1 22 2 72 −42 −10 −11 34 42 38 −90 19 −91 −1 −76
DA3 −34 42 55 95 98 −105 35 15 71 94 −9 10 24 −77
DA4 15 1 28 54 −29 44 11 80 18 36 14 30 5 −67
DA6 10 18 44 55 −11 −40 −13 −14 −18 28 −32 −13 9 −71
CP1 85 99 74 74 −14 −7 36 70 27 43 −10 −19 21 −83
CP2 71 100 67 74 −15 3 15 9 87 66 −5 −6 15 −90
CP3 77 99 42 54 −44 5 5 39 86 86 24 28 4 −87
CP5 62 100 65 71 −6 7 9 58 82 63 −19 −9 15 −75
CO1 19 43 53 57 −11 −26 29 24 34 20 −9 −5 24 −69
CO3 10 100 59 70 62 −6 −34 −22 99 95 −25 −18 4 −78
CO4 −20 14 38 90 84 16 29 29 12 18 11 50 35 −56
CL1  NT NT 64 67  NT  NT  NT  NT 95 72 −41 −26 NT  NT
CL3 100 52 65 47 21 −39 94 36 100 88 45 23 16 −82
CL4  NT NT 80 68 NT NT NT NT 84 33 −22 0  NT  NT
CA1 74 10 59 54 −16 −27 45 29 82 24 11 −4 19 −70
CA3 −44 11 60 65 11 −43 50 19 100 93 −20 −24 24 −72
CA4 53 94 53 87 31 100 47 −1 72 25 8 42 13 −68
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against PACF in the screening assay was not confirmed 
by the MIC assay.
Bactericidal activity of selected liposomal formulations
The liposomal formulations PA4, SA4 and CL3 were then 
subjected to testing for minimal bactericidal concentra-
tion (MBC) against S. epidermidis (Fig. 1). PA4 and SA4 
demonstrated strong bactericidal activity (MBC of 0.5 
and 0.25 μg/mL, respectively). In contrast, CL3 was not 
bactericidal at the tested concentrations, reducing the 
bacterial inoculum by no more than 75 %.
Effect of liposomes on vancomycin susceptibility
To address whether antimicrobial lipids in liposomal for-
mulation may have the potential to augment the effects 
of standard antibiotics, MIC of vancomycin was deter-
mined for VRE in the presence and absence of CL3, 
which alone—or its carrier liposomes—did not effect 
a substantial growth inhibition (see Table  3), or carrier 
liposomes. The MIC of vancomycin against VRE shifted 
from 64–32 μg/mL to as low as 4 μg/mL in the presence 
of 5 μg/mL CL3 (Fig. 2), which would be consistent with 
a shift from vancomycin resistant to susceptible, accord-
ing to CLSI-M100-S22. This suggests that liposomal 
lipids may potentiate or restore the efficacy of antibiotics 
against multidrug-resistant bacteria.
Hemolytic and cytotoxic activity of selected liposomal 
formulations
Prior to considering clinical use, a candidate compound 
must be evaluated for hemolytic and cytotoxic activity. PA4, 
SA4, and CL3 were subjected to hemolysis testing (Table 5) 
and cytotoxicity testing (Fig.  3). At high dose (900  μg/
mL test lipid) PA4 and SA4 effected over 40 % hemolysis 
within 30 min and CL3 within 3 h. However, when tested 
at 90 μg/mL test lipid (between 90 and 360 times the low-
est observed MIC) none of the formulations exhibited 
significant hemolysis over 3  h. Carrier-3 and carrier-4, in 
the absence of test lipid, also exerted hemolytic effects at 
the higher dose (both over 40 % hemolysis after 3 h), but 
did not cause hemolysis when tested at 90 μg/mL over 3 h 
(2.24 ± 0.6 and 1.64 ± 0.2 % hemolysis, respectively).
Table 4 Minimal inhibitory concentrations (MIC, given  in 
μg/mL) of  test lipids that  effected a growth inhibition 
of  >95  % against  at least two different bacterial strains 
in the screening assay
Shown are MIC values derived from two independent experiments each 
performed in triplicate. NT not tested because not susceptible in the screening 
assay
a See Table 1 for letter abbreviations; numbers indicate the type of liposomal 
formulation used
b SE multidrug-resistant Staphylococcus epidermidis ATCC 700566, VRE 
vancomycin resistant Enterococcus faecalis ATCC 700802, PACF Pseudomonas 
aeruginosa, cystic fibrosis isolate
Liposomal formulationa Bacterial strainb
SE VRE PACF
PA4 0.50 2 NT
SA4 0.25 0.50 NT
LA3 64 NT >64
CL3 1 NT 8
Fig. 1 Minimal bactericidal concentration of liposomal formulations 
in comparison with their minimal inhibitory concentration. Modified 
minimal inhibitory concentration (MIC) assay (square symbols, left 
y-axis) was performed with S. epidermidis followed by determination 
of minimal bactericidal concentration (round symbols, right y-axis). 
Test lipids were a palmitic acid prepared in carrier‑4 (PA4); b stearic 
acid prepared in carrier 4 (SA4); and c cholesteryl linoleate prepared 
in carrier‑3 (CL3). RFU relative fluorescence units. Dotted line bacterial 
inoculum (CFU/mL). Shown are means of two experiments con‑
ducted in duplicates
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Cytotoxic activity was evaluated with HepG2 cells at 
100 μg/mL employing the metabolic XTT assay (Fig. 3). 
While SA4 had significant inhibitory effects, cells treated 
with PA4 and CL3 were statistically not different from 
untreated cells. Carrier-3 and carrier-4, when tested 
alone, also exhibited cytotoxic effects (40.68 ±  12.54  % 
inhibition, p  <  0.05, and 83.97  ±  13.88  % inhibition, 
p < 0.001, respectively). This data suggests that the hemo-
lytic and cytotoxic activity of the liposomal formulations 
is at least in part contributed by the carrier lipid. Con-
sidering the varying activities of different lipids incorpo-
rated in the same carriers, a complex interaction between 
the different lipid species is likely.
Discussion
In this study, striving to address the urgent public health 
need posed by HAI with multidrug-resistant bacteria, 
we assessed the potential of free fatty acids and choles-
teryl esters as novel antibacterial agents. Liposomes of 
varying composition were employed as carrier for these 
lipophilic agents and these formulations were tested 
against Gram-positive and Gram-negative multidrug-
resistant bacteria involved in HAI using a modified MIC. 
The potential for restoring activity of conventional anti-
biotics was probed and hemolytic and cytotoxic activity 
assayed. Palmitic and stearic acid as well as cholesteryl 
linoleate were identified as the most promising com-
pounds whereby the carrier liposome formulation influ-
enced their activity.
To overcome interference of turbidity contributed by 
liposomes we employed the DNA probe Syto9 to quan-
tify bacterial growth in an otherwise standard MIC 
assay. Styo9 has been often used to quantify viable bac-
teria in biofilms [26, 27] but not yet been validated for 
use in MIC assays, which we did here using quality con-
trol strains and standard antibiotics. The modified DNA 
probe-based MIC assay may also be useful for testing 
fastidious organisms that require the addition of blood 
products in their growth media making turbidity based 
measurements including standard MIC testing obsolete.
Fig. 2 Minimal inhibitory concentration (MIC) of liposomal cholesteryl linoleate combined with standard antibiotic. Modified MIC assay with Syto 
9 fluorescence read out for vancomycin‑resistant Enterococcus faecalis incubated with vancomycin (V) in the presence and absence of cholesteryl 
linoleate prepared in carrier‑3 (CL3, 5 μg/mL). RFU relative fluorescence units. Shown are averages of triplicate measurements of two independent 
experiments (a, b) 
Table 5 Hemolytic activity of the most potent antimicrobial lipids
Hemolysis was screened at 900 μg/mL lipid concentration and further tested at 90 μg/mL lipid concentration (mean ± S.D., n = 3 for 30 min and 3 h time points and 
n = 1 for 24 h time point). PA4 palmitic acid prepared in carrier-4, SA4 stearic acid prepared in carrier-4, CL3 cholesteryl linoleate prepared in carrier-3
a There were no statistically significant differences compared to control erythrocytes after 30 min and 3 h
Liposomal formulation Hemolysis (% maximal hemolysis) at 900 μg/mL At 90 μg/mLa
30 min 3 h 24 h 30 min 3 h 24 h
PA4 >40 >40 >40 1.61 ± 0.50 3.10 ± 1.00 70.43
SA4 >40 >40 >40 2.21 ± 1.80 4.04 ± 0.60 46.35
CL3 <20 >40 >40 1.13 ± 0.20 0.80 ± 0.10 54.55
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Among the fatty acids and cholesteryl esters tested, pal-
mitic acid, stearic acid, and cholesteryl linoleate emerged 
as the most active lipids. Palmitic acid and stearic acid 
acted only against multidrug-resistant S. epidermidis and 
vancomycin resistant E. faecalis, both representing Gram-
positive cocci. This is in line with an earlier report on the 
preferential bactericidal activity of fatty acids against Gram-
positive bacteria [28] though the stated effective concentra-
tions of palmitic acid were substantially higher than what 
we describe here. The relatively decreased activity reported 
by Huang et al. [28] may be attributed to the use of etha-
nol-solubilized fatty acid without a carrier underlining the 
potential of liposomal formulations to reduce required 
active concentrations. Cholesteryl linoleate showed activity 
against the multidrug-resistant S. epidermidis and a P. aer-
uginosa strain but was less effective in killing than stearic 
acid and palmitic acid. This suggests that the cholesteryl 
ester may have a different mode of action.
We have identified host derived lipids that may have 
promise for future use as antimicrobials when applied 
alone or in combination with standard antibiotics. 
Plant lipids, namely essential oils, have long been used 
for their antibacterial activity in the food industry [29, 
30]. Recently, though, they have been also assessed for 
clinical use [31, 32], including the use as enhancer of 
antibiotics [33]. In a rabbit sepsis model, co-adminis-
tration of the polyunsaturated fatty acids linolenic and 
arachidonic acid with antibiotics enhanced killing of 
a multidrug-resistant P. aeruginosa strain [34]. Add-
ing lipophilic properties to antimicrobial peptides by 
N-acylation has also been proven to enhance their anti-
microbial activity [35, 36].
We observed that the carrier liposome composition 
influenced the test lipid activity and that some formula-
tion exhibited independent antibacterial activity. This 
suggests that phospholipid-mediated antimicrobial activ-
ity could contribute to the low MIC of palmitic acid and 
stearic acid. An interaction between the carrier lipids 
and the test lipids is also implicated by the changes in 
liposomes size depending on the constituents. Possi-
ble mechanisms of the observed liposome activity may 
include fusion and subsequent disruption of the bacterial 
cell membrane through lipid embedding into the phos-
pholipid bilayer and, for unsaturated lipids, lipid peroxi-
dation with radical production [15]. Such mechanistic 
studies are currently under way in our laboratory.
Bacterial and mammalian cell membranes both are 
composed of phospholipid bilayers. Thus, it is conceiv-
able that the antibacterial liposome formulations exhibit 
hemolytic and cytotoxic activity against mammalian cells. 
At concentrations ninety times or higher than the lowest 
MIC no hemolytic activity was observed within the first 
3 h but prolonged incubation resulted in hemolysis. This 
suggests that topical use may be a preferable treatment 
strategy for liposomal lipids. Cytotoxic effects through 
lipid peroxidation and mitochondria-initiated apoptosis 
have been well documented, in particular for unsaturated 
fatty acids such as linoleic acid [37, 38], and cytotoxic 
fatty acids are under investigation for intended use in can-
cer treatment [39, 40]. Here, we found that palmitic acid 
and cholesteryl linoleate did not cause significant growth 
inhibition of HepG2 cells but that stearic acid displayed 
significant cytotoxicity. Considering that the degree of 
antibacterial activity was influenced by the carrier compo-
sition and that the carriers also exerted some hemolytic 
and cytotoxic effects, careful selection and modification 
of the carrier lipids may yield antimicrobial formulations 
devoid of hemolytic and cytotoxic activity.
Liposomes have been previously used as carrier for 
antimicrobial compounds. For example, the antifun-
gal drug amphotericin B was successfully formulated in 
liposomes with greatly reduced cytotoxicity [41]. Other 
applications include liposomal delivery of antibiotics to 
pathogens entrapped in biofilms and intracellular patho-
gens [42, 43]. A major advantage of using liposomes as 
carrier for antimicrobial lipids (and other compounds) 
is the possibility to insert molecules that enable targeted 
delivery of the drug [44].
Fig. 3 Cytotoxic activity of the most potent antimicrobial lipids 
against the cell line HepG2. Metabolically active cells were quantified 
after 48 h incubation in the presence and absence of 100 μg/mL test 
lipid using the XTT assay. PA4 palmitic acid prepared in carrier‑4; SA4 
stearic acid prepared in carrier‑4; CL3 cholesteryl linoleate prepared 
in carrier‑3. Shown are mean ± S.D., n = 3. *p = 0.001 in one‑way 
ANOVA with Bonferroni posthoc analysis
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Conclusions
In summary, our results showed that selected fatty 
acids and cholesteryl esters packaged with phospholip-
ids exhibit antibacterial activity against Gram-positive 
and Gram-negative bacterial species and may aug-
ment the activity of antibiotics. Bactericidal activity 
could be unlinked from hemolytic and cytotoxic activ-
ity. The type of phospholipid carrier greatly influenced 
the activity. Thus, fatty acids and cholesteryl esters may 
have potential as novel lipophilic antimicrobial agents 
whereby modulating the phospholipid composition and 
incorporating tags may enable targeting specific types of 
bacteria.
Abbreviations
CFU: colony forming units; CL: cholesteryl linoleate; HAI: healthcare associ‑
ated infections; MBC: minimal bactericidal concentration; MDR: multi‑
drug resistant; MIC: minimal inhibitory concentration; PA: palmitic acid; 
RBC: red blood cell; RFU: relative fluorescence unit; SA: stearic acid; XTT: 
2,3‑Bis‑(2‑Methoxy‑4‑Nitro‑5‑Sulfophenyl)‑2H‑Tetrazolium‑5‑Carboxanilide.
Authors’ contributions
AHC conducted all modified MIC and MBC assays; drafted manuscript, revised 
and approved the final manuscript. NS performed MIC validation, revised 
and approved the final manuscript. RW conducted vancomycin synergism 
experiments, revised and approved the final manuscript. JG performed 
cytotoxicity testing, revised and approved the final manuscript. TQD, WE, 
and SMC designed and produced liposomes, revised and approved the final 
manuscript. SK performed hemolysis assays, revised and approved the final 
manuscript. HHX and GF participated in study design, revised and approved 
the final manuscript. EP designed the study, coordinated all experiments and 
communicated with all participants, co‑wrote the manuscript and revised. All 
authors read and approved the final manuscript.
Author details
1 Department of Biological Sciences, California State University Los Angeles, 
5151 State University Drive, Los Angeles, CA 90032, USA. 2 Molecular Express, 
Inc., Rancho Dominguez, CA, USA. 
Acknowledgements
We thank Yessenia Velazco for technical assistance and Dr. Susan Kane for 
advice on cytotoxicity testing.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data are shown in the manuscript.
Funding
NIH Grants 1SC1GM096916, 1P20CA118783‑01A1, 1P20CA118775‑01A, 
1P20MD001824, and MBRS RISE R25 GM61331; Army Research Office 
W911NF‑12‑1‑0059; CSUPERB Entrepreneurial Joint Venture Matching Grant 
Program.
Received: 22 March 2016   Accepted: 28 June 2016
Additional file
Additional file 1: Table S1. Test lipid composition and particle size.
References
 1. Tangden T, Giske CG. Global dissemination of extensively drug‑resistant 
carbapenemase‑producing Enterobacteriaceae: clinical perspec‑
tives on detection, treatment and infection control. J Intern Med. 
2015;277:501–12.
 2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, 
Limbago B, Fridkin S, Network National Healthcare Safety, et al. Antimicro‑
bial‑resistant pathogens associated with healthcare‑associated infections: 
summary of data reported to the National Healthcare Safety Network at 
the Centers for Disease Control and Prevention, 2009‑2010. Infect Control 
Hosp Epidemiol. 2013;34:1–14.
 3. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, 
Lynfield R, Maloney M, McAllister‑Hollod L, Nadle J, et al. Multistate point‑
prevalence survey of health care‑associated infections. N Engl J Med. 
2014;370:1198–208.
 4. Centers for disease control and prevention. 2013 National and state 
healthcare‑associated infections progress report. Published January 14, 
2015. www.cdc.gov/hai/progress‑report/index.html. 2015.
 5. Harbarth S, Theuretzbacher U, Hackett J, consortium DA. Antibiotic 
research and development: business as usual. J Antimicrob Chemother. 
2015;70:1604–7.
 6. Theuretzbacher U. Recent FDA antibiotic approvals: good news and bad 
news. In: The center for disease dynamics, economics & policy, vol. 12. 
Washington DC 2015.
 7. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov. 
2013;12:371–87.
 8. Eckert R. Road to clinical efficacy: challenges and novel strategies for 
antimicrobial peptide development. Future Microbiol. 2011;6:635–51.
 9. Tavares LS, Silva CS, de Souza VC, da Silva VL, Diniz CG, Santos MO. Strate‑
gies and molecular tools to fight antimicrobial resistance: resistome, 
transcriptome, and antimicrobial peptides. Front Microbiol. 2013;4:412.
 10. Xu HH, Trawick JD, Haselbeck RJ, Forsyth RA, Yamamoto RT, Archer R, 
Patterson J, Allen M, Froelich JM, Taylor I, et al. Staphylococcus aureus 
targetarray: comprehensive differential essential gene expression as a 
mechanistic tool to profile antibacterials. Antimicrob Agents Chemother. 
2010;54:3659–70.
 11. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller 
A, Schaberle TF, Hughes DE, Epstein S, et al. A new antibiotic kills patho‑
gens without detectable resistance. Nature. 2015;517:455–9.
 12. Porter E, Ma DC, Alvarez S, Faull KF. Antimicrobial lipids: emerging effector 
molecules of innate host defense. World J Immunol. 2015;5:51–61.
 13. Lipids and essential oils as antimicrobial agents. Chichester: Wiley; 2011.
 14. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH Jr, Murphy RC, 
Raetz CR, Russell DW, Seyama Y, Shaw W, et al. A comprehensive clas‑
sification system for lipids. J Lipid Res. 2005;46:839–61.
 15. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms 
of action and biotechnological potential. Appl Microbiol Biotechnol. 
2010;85:1629–42.
 16. Do TQ, Moshkani S, Castillo P, Anunta S, Pogosyan A, Cheung A, Marbois 
B, Faull KF, Ernst W, Chiang SM, et al. Lipids including cholesteryl linoleate 
and cholesteryl arachidonate contribute to the inherent antibacterial 
activity of human nasal fluid. J Immunol. 2008;181:4177–87.
 17. Fujii G, Chang JE, Coley T, Steere B. The formation of amphotericin B ion 
channels in lipid bilayers. Biochemistry. 1997;36:4959–68.
 18. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adlermoore JP. Pharmacol‑
ogy and toxicology of a liposomal formulation of amphotericin B (AmBi‑
some) in rodents. J Antimicrob Chemother. 1991;28(Suppl B):49–61.
 19. Kohli AG, Kierstead PH, Venditto VJ, Walsh CL, Szoka FC. Designer lipids for 
drug delivery: from heads to tails. J Control Release. 2014;190:274–87.
 20. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand‑targeted 
liposome design: challenges and fundamental considerations. Trends 
Biotechnol. 2014;32:32–45.
 21. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Adler‑Moore 
JP, Fujii G. Protection against H1, H5, H6 and H9 influenza A infection with 
liposomal matrix 2 epitope vaccines. Vaccine. 2006;24:5158–68.
 22. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria 
that grow aerobically; Approved standard‑ninth edition. CLSI document 
M07‑A19. In: Wayne PA. Clinical and Laboratory Standards Institute; 2012.
Page 11 of 11Cheung Lam et al. BMC Res Notes  (2016) 9:337 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 23. CLSI. M26‑A: Methods for determining bactericidal activity of antimi‑
crobial agents; Approved Guideline. In: Wayne PA. Clinical Laboratory 
Standards Institute; 1999.
 24. Zander R, Lang W, Wolf HU. Alkaline haematin D‑575, a new tool for the 
determination of haemoglobin as an alternative to the cyanhaemiglobin 
method. I. Description of the method. Clin Chim Acta. 1984;136:83–93.
 25. Tew GN, Clements D, Tang H, Arnt L, Scott RW. Antimicrobial activ‑
ity of an abiotic host defense peptide mimic. Biochim Biophys Acta. 
2006;1758:1387–92.
 26. Cao B, Christophersen L, Thomsen K, Sonderholm M, Bjarnsholt T, Jensen 
PO, Hoiby N, Moser C. Antibiotic penetration and bacterial killing in 
a Pseudomonas aeruginosa biofilm model. J Antimicrob Chemother. 
2015;70:2057–63.
 27. Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for 
quantification of microbial biofilms grown in microtiter plates. J Microbiol 
Methods. 2008;72:157–65.
 28. Huang CB, Alimova Y, Myers TM, Ebersole JL. Short‑ and medium‑chain 
fatty acids exhibit antimicrobial activity for oral microorganisms. Arch 
Oral Biol. 2011;56:650–4.
 29. Seow YX, Yeo CR, Chung HL, Yuk HG. Plant essential oils as active antimi‑
crobial agents. Crit Rev Food Sci Nutr. 2014;54:625–44.
 30. Juneja VK, Dwivedi HP, Yan X. Novel natural food antimicrobials. Annu Rev 
Food Sci Technol. 2012;3:381–403.
 31. Mantle D, Gok MA, Lennard TW. Adverse and beneficial effects of plant 
extracts on skin and skin disorders. Adverse Drug React Toxicol Rev. 
2001;20:89–103.
 32. Martin KW, Ernst E. Herbal medicines for treatment of bacterial infec‑
tions: a review of controlled clinical trials. J Antimicrob Chemother. 
2003;51:241–6.
 33. Langeveld WT, Veldhuizen EJ, Burt SA. Synergy between essential oil 
components and antibiotics: a review. Crit Rev Microbiol. 2014;40:76–94.
 34. Giamarellos‑Bourboulis EJ, Mouktaroudi M, Adamis T, Koussoulas V, 
Baziaka F, Perrea D, Karayannacos PE, Giamarellou H. n‑6 polyunsaturated 
fatty acids enhance the activities of ceftazidime and amikacin in experi‑
mental sepsis caused by multidrug‑resistant Pseudomonas aeruginosa. 
Antimicrob Agents Chemother. 2004;48:4713–7.
 35. Joshi S, Dewangan RP, Yadav S, Rawat DS, Pasha S. Synthesis, antibacterial 
activity and mode of action of novel linoleic acid‑dipeptide‑spermidine 
conjugates. Org Biomol Chem. 2012;10:8326–35.
 36. Zweytick D, Deutsch G, Andra J, Blondelle SE, Vollmer E, Jerala R, Lohner 
K. Studies on lactoferricin‑derived Escherichia coli membrane‑active 
peptides reveal differences in the mechanism of N‑acylated versus non‑
acylated peptides. J Biol Chem. 2011;286:21266–76.
 37. Rial E, Rodriguez‑Sanchez L, Gallardo‑Vara E, Zaragoza P, Moyano E, 
Gonzalez‑Barroso MM. Lipotoxicity, fatty acid uncoupling and mitochon‑
drial carrier function. Biochim Biophys Acta. 2010;1797:800–6.
 38. Das UN. Essential fatty acids, lipid peroxidation and apoptosis. Prostaglan‑
dins Leukot Essent Fatty Acids. 1999;61:157–63.
 39. Murray M, Hraiki A, Bebawy M, Pazderka C, Rawling T. Anti‑tumor activi‑
ties of lipids and lipid analogues and their development as potential 
anticancer drugs. Pharmacol Ther. 2015;150:109–28.
 40. Fauser JK, Prisciandaro LD, Cummins AG, Howarth GS. Fatty acids as 
potential adjunctive colorectal chemotherapeutic agents. Cancer Biol 
Ther. 2011;11:724–31.
 41. Adler‑Moore J, Proffitt RT. Am Bisome: liposomal formulation, structure, 
mechanism of action and pre‑clinical experience. J Antimicrob Chem‑
other. 2002;49(Suppl 1):21–30.
 42. Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans 
K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. 
J Control Release. 2014;190:607–23.
 43. Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solu‑
tion to treat intracellular bacterial infections. Int J Antimicrob Agents. 
2014;43:485–96.
 44. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to 
clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
